DMCPA, also known as 2,5-dimethoxy-4-methylphenylcyclopropylamine, is a psychedelic drug of the phenethylamine, amphetamine, and phenylcyclopropylamine families related to DOM. It is a derivative of tranylcypromine and is the cyclized phenethylamine analogue of DOM in which the α and β positions have been connected with a carbon atom to form a cyclopropyl group.
Use and effects In his book PiHKAL (Phenethylamines I Have Known and Loved), Alexander Shulgin lists DMCPA's dose as 15 to 20mg orally and its duration as 4 to 8hours. DMCPA Entry in PiHKAL Its onset is 1hour. The effects of DMCPA have been reported to include psychedelic visuals such as visual movement, fantasy, eroticism, feeling decoupled from one's experience and environment, feeling like the aura before a seizure, lightheadedness, feeling loss of control and uncomfortable, muscle tremors, mild anorexia, bizarre and colorful dreams during subsequent sleep, and no next-day hangover. It was said to have too much in the way of physical side effects and hints of physical toxicity at the highest assessed dose.
Interactions
Pharmacology Pharmacodynamics The comprehensive receptor interactions of DMCPA have been studied.
Chemistry Synthesis The chemical synthesis of DMCPA has been described.
Analogues Analogues of DMCPA include 3,4,5-trimethoxytranylcypromine (TMT), tranylcypromine, and DOM, among others.
History DMCPA was first described in the scientific literature by at least 1974.
Society and culture Legal status United Kingdom This substance is a Class A drug in the Drugs controlled by the UK Misuse of Drugs Act.
See also Substituted methoxyphenethylamine Cyclized phenethylamine Phenylcyclopropylamine
References
External links 25D-CPA (DMCPA) - Isomer Design DMCPA - PiHKAL - Erowid DMCPA - PiHKAL - Isomer Design DMCPA - The Shulgin Index